NCT05336383View on ClinicalTrials.gov

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2022

Primary Completion Date

December 7, 2026

Study Completion Date

December 7, 2026

Conditions
Multiple MyelomaPlasma Cell NeoplasmMalignant Plasma Cell Neoplasm
Interventions
DRUG

Radiation Therapy

Given by Infusion

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER